KRAS and colorectal carcinoma: In CRC, KRAS mutations lead to abnormal activation of it RAS/RAF/MEK/ERK signaling pathway, upregulating IGF-1R expression via a novel MEK-SP1-DNMT1-miR-137 pathway in CRC cells to promote liver metastasis35.